{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:12:41Z","timestamp":1786356761787,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.vaccine.2017.08.083","type":"journal-article","created":{"date-parts":[[2017,9,9]],"date-time":"2017-09-09T08:47:40Z","timestamp":1504946860000},"page":"6329-6335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage"],"prefix":"10.1016","volume":"35","author":[{"given":"Triin","family":"V\u00f5rno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Lutsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneli","family":"Uusk\u00fcla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Padrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje","family":"Raud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Reile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Nahkur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul-Allan","family":"Kiivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.08.083_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","article-title":"Epidemiology of genital human papillomavirus infection","volume":"102","author":"Koutsky","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.vaccine.2017.08.083_b0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.083_b0015","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/erv.09.123","article-title":"Currently approved prophylactic HPV vaccines","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2017.08.083_b0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vaccine.2006.06.015","article-title":"Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease","volume":"24","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2017.08.083_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: the burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.083_b0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.08.083_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-11-13","article-title":"Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis","volume":"11","author":"Lu","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.083_b0040","first-page":"1","article-title":"Status of new vaccine introduction \u2013 worldwide, September 2016","volume":"92","author":"Loharikar","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.08.083_b0045","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2017.08.083_b0050","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.083_b0055","unstructured":"International Agency for Research on Cancer. Globocan 2012. IARC; 2015."},{"key":"10.1016\/j.vaccine.2017.08.083_b0060","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2017.08.083_b0065","first-page":"20","article-title":"Significantly increased cervical cancer incidence in Estonia [Estonian: Oluliselt suurenenud haigestumus emakakaelav\u00e4hki Eestis perioodil 1998\u20132008]","volume":"95","author":"Nyg\u00e5rd","year":"2016","journal-title":"Eesti Arst"},{"key":"10.1016\/j.vaccine.2017.08.083_b0070","unstructured":"National Institute for Health Development, Estonian Cancer Screening Registry. Target population cervical cancer screening participation in 2015 by counties [Estonian: 2015. aasta emakakaelav\u00e4hi s\u00f5eluuringu sihtr\u00fchma osalus maakondade l\u00f5ikes] http:\/\/www.tai.ee\/images\/PDF\/Klassifikaatorid\/5.EKV2015_sihtr%C3%BChma_osalus.pdf [accessed 17.03.2017]."},{"key":"10.1016\/j.vaccine.2017.08.083_b0075","unstructured":"Estonian Health Insurance Fund. Patient-level data on Pap-tests performed on Estonian women in 2009 [data on file]; 2009."},{"key":"10.1016\/j.vaccine.2017.08.083_b0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2334-10-63","article-title":"Population-based type-specific prevalence of high-risk human papillomavirus infection in Estonia","volume":"10","author":"Uusk\u00fcla","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.083_b0085","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/eurpub\/ckp208","article-title":"Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia","volume":"20","author":"Obradovic","year":"2010","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.vaccine.2017.08.083_b0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis","volume":"6","author":"Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.vaccine.2017.08.083_b0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2334-9-119","article-title":"Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model","volume":"9","author":"Insinga","year":"2009","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.083_b0100","unstructured":"V\u00f5rno T, Nahkur O, Uusk\u00fcla A, Padrik L, Raud T, Reile R. The cost-effectiveness of HPV vaccination [Estonian: HPV-vastaste vaktsiinide kulut\u00f5husus]. Tartu: University of Tartu, Department of Public Health; 2015. <http:\/\/rahvatervis.ut.ee\/handle\/1\/6465>."},{"key":"10.1016\/j.vaccine.2017.08.083_b0105","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2013.06.064","article-title":"Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study","volume":"31","author":"Brisson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.083_b0110","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ijc.28541","article-title":"Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine","volume":"134","author":"Drolet","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2017.08.083_b0115","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/cncr.23764","article-title":"HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women","volume":"113","author":"Gillison","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2017.08.083_b0120","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/1471-2407-14-968","article-title":"Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis","volume":"14","author":"Abogunrin","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2017.08.083_b0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"Hartwig","year":"2015","journal-title":"Papillomavirus Res"},{"issue":"6","key":"10.1016\/j.vaccine.2017.08.083_b0130","doi-asserted-by":"crossref","first-page":"djv086","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2017.08.083_b0135","unstructured":"Statistics Estonia. Statistical database: Table XO02: Consumer Price Index, 1997 = 100 (months), last updated 07.08.2017. http:\/\/pub.stat.ee\/px-web.2001\/I_Databas\/Economy\/24Prices\/24Prices.asp [accessed 18.08.2017]."},{"key":"10.1016\/j.vaccine.2017.08.083_b0140","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2334-13-304","article-title":"The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia","volume":"13","author":"Uusk\u00fcla","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.083_b0145","unstructured":"Estonian Health Insurance Fund. Patient-level data on cervical cancer costs in 2011\u20132014 [data on file]; 2015."},{"key":"10.1016\/j.vaccine.2017.08.083_b0150","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1016\/j.vaccine.2009.06.039","article-title":"Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria","volume":"27","author":"Zechmeister","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.083_b0155","unstructured":"Statistics Estonia. Statistical database: Table ML260: Employees in main job by sex, age group and full\/part-time job, last updated 14.02.2017. <http:\/\/pub.stat.ee\/px-web.2001\/I_Databas\/Social_life\/09Labour_market\/06Employees\/02Annual_statistics\/02Annual_statistics.asp> [accessed 18.08.2017]."},{"key":"10.1016\/j.vaccine.2017.08.083_b0160","unstructured":"Statistics Estonia. Statistical database: Table PO0211: Mean annual population by sex and age group, last updated 8.05.2017. http:\/\/pub.stat.ee\/px-web.2001\/I_Databas\/Population\/01Population_indicators_and_composition\/04Population_figure_and_composition\/04Population_figure_and_composition.asp [accessed 18.08.2017]."},{"key":"10.1016\/j.vaccine.2017.08.083_b0165","unstructured":"Estonian Health Insurance Fund. Statistics of monetary benefits: Incapacity benefit costs 2011-2016(xls) [Estonian: Rahaliste h\u00fcvitiste statistika: T\u00f6\u00f6v\u00f5imetush\u00fcvitise kulud 2011\u20132016]. <https:\/\/www.haigekassa.ee\/et\/haigekassa\/statistika\/rahaliste-huvitiste-kulud\/> [accessed 18.08.2017]."},{"key":"10.1016\/j.vaccine.2017.08.083_b0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0266462310000085","article-title":"Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark","volume":"26","author":"Olsen","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vaccine.2017.08.083_b0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1071\/SH07043","article-title":"A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program","volume":"4","author":"Kulasingam","year":"2007","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2017.08.083_b0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.083_b0185","first-page":"627","article-title":"Evaluation of health economics: decision trees and Markov models [Estonian: Modelleerimine tervise\u00f6konoomikas otsustuspuu ja Markovi mudeli abil]","volume":"93","author":"Juus","year":"2014","journal-title":"Eesti Arst"},{"key":"10.1016\/j.vaccine.2017.08.083_b0190","unstructured":"Statistics Estonia. Statistical database: Table NAA0013: Gross Domestic Product and Gross National Income (ESA 2010), last updated 31.05.2017. <http:\/\/pub.stat.ee\/px-web.2001\/I_Databas\/Economy\/23National_accounts\/01Gross_domestic_product_(GDP)\/12Main_national_accounts_indicators\/12Main_national_accounts_indicators.asp> [accessed 18.08.2017]."},{"key":"10.1016\/j.vaccine.2017.08.083_b0195","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study","volume":"2","author":"Jit","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2017.08.083_b0200","unstructured":"Liiv K, Lutsar K, Palm E, Uusk\u00fcla A, Kiivet R-A. Cost-effectiveness of human papillomavirus vaccines in Estonia [Estonian: Inimese papilloomiviiruse vastaste vaktsiinide kulut\u00f5husus Eestis]. Tartu: University of Tartu, Department of Public Health; 2011. <http:\/\/rahvatervis.ut.ee\/handle\/1\/4921>"},{"key":"10.1016\/j.vaccine.2017.08.083_b0205","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.vaccine.2017.08.083_b0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T07:29:10Z","timestamp":1536046150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17311830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":42,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0264410X17311830"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}